Capital Cell

Capital Cell (legal name PFP CAPITAL CELL S.L.) is an active EU-based equity crowdfunding platform headquartered in Barcelona, Spain. It specialises in early-stage biotechnology and life sciences investments and is authorised by the Spanish Securities Market Commission (CNMV) under the European Crowdfunding Service Providers regulation (ECSP) [1][2]. The platform reports having completed 161 funding rounds and approximately €153 million invested, with a reported portfolio value multiplier of 2.7x on its website (figures shown on the platform) [2].

Why this matters: the CNMV authorisation confirms that Capital Cell operates under EU crowdfunding rules rather than UK FCA rules, which has direct consequences for the regulatory protections available to UK investors [1][4].

Capital Cell lists and vets early-stage life sciences companies for equity raises, presenting opportunities to individual investors who can commit capital online. The platform states that funds are held and released according to the terms of each round and that funding is only released once the target is met, consistent with standard crowdfunding mechanics [2].

Selection and due diligence. Capital Cell describes a screening process and industry review for projects; third-party write-ups reference a specialised expert network and a selective acceptance rate, but the exact membership and the 3% acceptance figure are not corroborated on the platform's own site and should be treated as unconfirmed unless the platform publishes a detailed methodology [2].

Why this matters: investors should know that platform screening does not eliminate high failure risk in early-stage biotech — due diligence and understanding of scientific and regulatory hurdles remain essential.

Asset class. Equity in unlisted early-stage healthtech and biotech companies (pre-seed to seed+). Platform materials and public pages indicate a specialised focus on biotech/life sciences [2].

• Minimums. Some third-party summaries suggest minimum investments can be relatively low (e.g. €100–€1,000), but the platform's current public pages should be checked for each offer because minimums are set per project and are not consistently confirmed in public sources.
• Fees. External summaries report an 8% commission charged to companies on capital raised and an SPV management fee schedule (annual fees of approximately €3,084 to €9,000 depending on amount raised). These fees are commonly cited in market write-ups but are not clearly documented on the platform's own site and should be verified directly with Capital Cell before relying on them [5].
• Retraction/withdrawal. The platform references a short investor withdrawal (retraction) window common in EU crowdfunding (for example, a 7-day period is mentioned in third-party materials), but investors should confirm the exact cooling-off and cancellation mechanics for each round in the offer documents [2].
• Secondary market. Capital Cell references mechanisms for investor-to-investor transfers in certain cases; the degree to which this provides reliable liquidity is limited and typically requires negotiation between investors.

Why this matters: fee structures, minimums and secondary market rules materially affect net returns and the ability to exit — confirm these details on each offer's documentation before investing.

Capital Cell is aimed at investors seeking exposure to early-stage biotechnology and life sciences companies and who understand and accept high risk, long holding periods and potential total loss of capital [2]. It is not suited for investors seeking liquid, short-term returns.

Why this matters: the investor profile determines suitability — early-stage biotech requires patience, sector knowledge or willingness to accept specialist risk, and a capacity to bear losses.

Regulatory status.

• Capital Cell (PFP CAPITAL CELL S.L.) is authorised by the Spanish CNMV as a Participatory Financing Service Provider under Regulation (EU) 2020/1503 (ECSP) — this is the firm's primary regulator [1].
• The firm is not listed as directly authorised by the UK Financial Conduct Authority (FCA) and no UK Firm Reference Number (FRN) for Capital Cell was found in the FCA register search included in the research [4].

Implications for UK investors. If you are a UK resident using an ECSP-authorised platform that is not FCA-authorised, UK regulatory protections such as FSCS compensation and the UK Financial Ombudsman Service will typically not apply to the platform itself. UK investors should consider whether the platform's governance, custody arrangements and complaints process meet their expectations before investing [1][4].

Complaints procedure. Capital Cell publishes a complaints and grievances procedure and provides contact routes (e.g. email) for registered complaints; it aims to resolve complaints within stated internal timeframes, but investors should retain documentation and consider local dispute-resolution options if necessary [6].